Zymergen Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Add...
April 26 2021 - 4:05PM
Zymergen Inc. (“Zymergen”), one of the world’s foremost
biofacturing companies, today announced the closing of its initial
public offering of 18,549,500 shares of its common stock, including
the full exercise by the underwriters of their option to purchase
2,419,500 additional shares of common stock, at a public offering
price of $31.00 per share. The shares are listed on the Nasdaq
Global Select Market under the ticker symbol “ZY”. The gross
proceeds from the offering to Zymergen, before deducting
underwriting discounts and commissions and other offering expenses
payable by Zymergen, are approximately $575 million.
J.P. Morgan and Goldman Sachs & Co. LLC are acting as lead
book-running managers for the offering. BofA Securities, Cowen and
UBS Investment Bank are acting as book-running managers. Lazard is
acting as co-manager.
The offering was made only by means of a prospectus. Copies of
the final prospectus may be obtained from: J.P. Morgan
Securities LLC, Attention: Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717 or by telephone at
866-803-9204 or by email at prospectus-eq_fi@jpmorganchase.com; or
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200
West Street, New York, NY 10282, by telephone at (866) 471-2526 or
by email at prospectus-ny@ny.email.gs.com.
Registration statements relating to the sale of
these securities have been filed with, and declared effective by,
the Securities and Exchange Commission. This press release shall
not constitute an offer to sell or the solicitation of an offer to
buy these securities, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.
About ZymergenZymergen is a biofacturing
company using biology to reimagine the world. Zymergen partners
with nature to design, develop and manufacture bio-based
breakthrough products that deliver value to customers in a broad
range of industries. A unique combination of biology, chemistry,
software and automation enables the company to design and create
new materials.
Investor ContactNiraj
Javeriinvestors@zymergen.com
Media ContactMike
Dulinmdulin@zymergen.com502-777-2029
Zymergen (NASDAQ:ZY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zymergen (NASDAQ:ZY)
Historical Stock Chart
From Apr 2023 to Apr 2024